Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
All this focus on France.
We should be looking across the pond for the real news !!
FOMO will kick in soon :-)
Massive news will land soon !
Exciting news I agree
Found by Cola in the amazing Reddit group !!
Sorry link below
https://commonsbusiness.parliament.uk/document/45518/pdf
178 Chi Onwurah (Newcastle upon Tyne Central): To ask the Secretary of State for
Health and Social Care, what steps he has taken to ensure that inhaled interferon beta is manufactured in the UK in the event that final-stage clinical trials of the
drug prove effective in treating covid-19. (158041)
179 Chi Onwurah (Newcastle upon Tyne Central): To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of placing advance orders for inhaled interferon beta, which is being trialled as a treatment for covid-19 in Newcastle’s Royal Victoria Infirmary and other hospitals.
(158042
There is two trials using interferon in France.
This is excellent news as it drives awareness.
The even better news is our mega strong patents (helped by that Dragons Den chap), covers us for Interferon Beta A and B and Lambada !
So we can all sleep easy tonight knowing we have the best formulation, the most effective formulation and a patent that covers this breakthrough market.
See question on P21
Newcastle is live. MP asking about pre orders.
Thanks to Cola on Reddit!
In order to identify the most promising studies, a national prioritization system has been put in place by the Government. It is based on the award of the "National Research Priority" label by the ad hoc national steering committee for therapeutic trials and other research (CAPNET).
To date, CAPNET has awarded the "national research priority" label to 22 studies already underway or for which an authorization request has been submitted.
These 22 projects are presented below, and illustrate the potential of French biomedical research and its strong mobilization to increase knowledge about Covid-19 and offer new treatments. However, they do not concern vaccine trials, which are subject to prioritization by a specific mechanism.
SPRINTER, promoted by Synairgen, is an international, multi-center trial to investigate the efficacy of inhaled beta-interferon in hospitalized patients. Trials Evaluating Treatments for Mild and Moderate Forms
We have National Research Priority in France along with 21 other treatments.
This is confirmed :
https://solidarites-sante.gouv.fr/soins-et-maladies/maladies/maladies-infectieuses/coronavirus/professionnels-de-sante/recherche-sur-la-covid-19/etudes-cliniques-labellisees-priorite-nationale-de-recherche-sur-la-COVID-19
We all know if Synairgen was listed in America the MCAP would be well over 1 billion by now. There are so many examples to back this up.
We also know that the share price will be manipulated on low volumes and will swing quickly.
So I switch off from the daily swings. I do try and top up on the lows and if this enters 150’s again I have funds ready.
I expect news in March. I am ultra excited about the opportunity here. Let the A trades go fishing, they won’t catch my shares !!
Hold for gold. #endgame !!
I wanted to add that I am desperately upset to hear everyone’s stories.
I agree every house in the U.K. should have an Oximeter.
Any drop into low 90’s and call 111.
You know things are good for a company when they get mentioned in Forbes !
https://www.forbes.com/sites/markminevich/2021/02/24/surviving-covid-19-does-not-mean-thriving-but-advanced-technology-could-promote-a-better-life-experience--recovery/amp/
One other observation.
Back in July the week before manic Monday. We had trolls shouting sell and chart experts saying “down trend”.
This share is impossible to read. We know what we have here and we know data data data is king. “It’s all about de-risking as much as possible so the buyer pays more” and “it’s all about the end game”
Well that end game might just start next month with a cheeky offer. Let’s see !!!!
Morning
It was good to see Sir Stephen last night look so confident talking about Synairgen. He use a interesting word “portfolio” of treatments. I wonder what he meant.
On positive Home and Hospital trials I guess we will
Be treating different stages of the virus. We also know they were looking at ventilation and also long Covid.
Very happy to be holding and pleased I grabbed a few more on the drop !
This share is way under valued when compared to our cousins across the Atlantic in a similar position. The Institutions will see this and will be adding.
I expect news to land well before Q2 arrives !!
Hence I’m adding whilst some sell.
One of us is right :-)
Direct from their report
“All four scenarios modelled lead to a substantial resurgence in hospital admissions and death”
This is just the U.K.
I believe this report doesn’t model in mutation of virus.
The role for SNG001 is becoming stronger !
Many people on here today trying to talk down Synairgen.
So Polar, FDA and NIHR/MHRA have authorised the various trials and flagged them urgent just for the fun of it.... clearly not.
The SAGE document makes it very clear to me and those bothered to read it, that treatments will become increasingly important going forward.
I also listened to Dr Woodstock in America this evening. Her panel made a good point. “We need to test any booster vaccines to make sure we don’t overload, we need to make sure this strategy is safe and effective”. I like to listen to the US as that is what counts for Synairgen.
Activ2 was a massive milestone for Synairgen. Whilst trolls seem to only focus on the U.K. to be honest it’s the rest of the world that matters !
Also if you look at the differences between Government briefings and the Sage report... you will see this is now where close to being over. ( sorry for the negativity).
Vaccines play a clear role alongside treatments!!
I always remember RM saying this would be an investors share and it’s all about the end game. I guess that is why the likes of Polar own over 10% of the company.
Some of the comments on here quoting efficacy numbers of the vaccines, clearly don’t understand SNG001 and the broad spectrum anti viral design. They also clearly don’t want to understand it.
Synairgen is on a FDA backed / funded Phase2/3 trial. Synairgen has a (up to) 20 country Phase3 trial live.
Management at Synairgen will soon see first data from the closed Phase2 U.K. Home trials.
Investors here will not be impacted by the virus that populates this board. We have the best Covid19 drug to hand. Yes even broad enough to wipe out the scum virus on this board.
Exciting few weeks ahead. I think we will be surprised just how quickly news lands.
GLA.
Some people are questioning who would sell ?
I believe we are seeing the placing shares trades from a few sellers to two major buyers.
I’m expecting TR1 updates soon !
Morning all. You really need to make the subject more PMA!
So what we are seeing now is a game of hungry hippo!
We have at least one major buyer. We also have a number of 175p placement shares being presented to the offer. This is the first time in a while these shares could be sold for a profit. So we will see some churn at this level whilst our hippos feed.
We have experienced this many times with this share over the last 11 months. However unlike any other time, I believe the hippos will keep buying and by Friday we will smash the 200p.
Unlike any other time before, we also have Activ2 running as an open trial. If the FDA like what they see, this could instantly convert into a Phase3 trial with EUA and pre order.
This could happen February or March. It is because of this the hippos are so hungry!
Let’s also not forget we have Phase2 placebo Home trial data due Q2. I think Marsden wants this releases March to support the Activ2 decision.
Then we have Phase3 hospitals. This is such an exciting trial given the depth of data from across the world. Synairgen’s Biobank will be overflowing soon !
So some might choose to trade this share, but for me it’s a keeper. I am sitting on my hands and watching the hippos feed. Exciting weeks ahead folks.
As one last forecast. I think we will see an offer land March, inline with the switch from Activ2 Phase2 to Phase3.
Very good afternoon to all.
What an achievement for this little British company.
Our MCAP is tiny compared to US companies at the same stage of development.
First dose confirmed. The trial will fill quick. Synairgen have tight control over patient type, so we are protecting our data.
On positive results in Phase2 we could see FDA confirm our safety data is sufficient to allow EUA. We would then complete Phase3 alongside EUA
Truly exciting. Well done Richard Marsden and the team.
Also Phase3 update on route !!!